Biopharmaceutical Company with Innovative Cancer Therapeutics in Clinical Trials

DOWNLOAD NDA

Project Franklin

Hilco are pleased to offer for sale the assets of a biopharmaceutical company developing innovative drug candidates to address oncology and haematology indications.

Overview

Experienced company in mechanism targeted small molecules to treat a range of cancer types.
Strong clinical indications and landscape potential to progress novel candidate molecules further into single, and combination therapy studies.
Specialise in transcription regulation, epigenetics and cell-cycle biology.
Approximately £54 million invested into two key drug candidate programs.
Team of 6 employees with extensive experience in research, preclinical and clinical development, and commercialisation.

Business Assets

Novel Drug Candidate Pipeline – Drug candidates in Phase 1 and Phase 2 clinical trials.
Extensive clinical trial data set
Intellectual Property – A portfolio of patents and trademarks, clinical protocols, clinical data, ongoing experimental work, compound synthesis pathways, and other proprietary information.
WIP – Ongoing clinical trials and exploratory scientific research.

Sale Process and Further Information

Offers Invited

Please register your interest and direct any questions in the first instance Sophie Felstead (sfelstead@hilcoglobaladvisors.co.uk), Nick Hughes (nhughes@hilcoglobaladvisors.co.uk) and Roland Cramp (rcramp@hilcoglobaladvisors.co.uk) of Hilco, who will be able to provide access to a data room of further information on the signing of a confidentiality agreement and answer any questions you have at this stage. Terms and conditions related to the sale can be provided on request.

Terms and Conditions

No warranties, express or implied, are provided in relation to any information or statements made in connection to this opportunity. The information contained herein, and within the project dataroom, has not been verified by Hilco and prospective purchasers must undertake their own due diligence to satisfy themselves as to the accuracy of all such information and any statements made. Hilco’s full Terms and Conditions apply. Hilco acts as agent for the Vendor who offers for sale only such right, title and interest the Company possesses in the assets.